Amsterdam-based UniQure NV priced its public offering of common shares, which aims to raise gross proceeds of $225 million.
The biotechnology company is selling 4,891,305 ordinary shares at $46 apiece in the offering expected to close Sept. 10.
The company has granted a 30-day option to underwriters to purchase up to 733,695 additional ordinary shares at the same price.
Goldman Sachs & Co. LLC and SVB Leerink are acting as joint book-running managers, Stifel is book-running manager, while Cantor Fitzgerald & Co. and SunTrust Robinson Humphrey are co-lead managers.
H.C. Wainwright & Co. is co-manager for the offering.
